Company intelligence / Profile preview

Reprogenetics

Livingston, New Jersey, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Commercial

Overview

Reprogenetics was a leading provider of preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS), offering advanced technologies such as high-resolution next-generation sequencing and comparative genomic hybridization to improve embryo selection for IVF. The company published extensively on the clinical value of these techniques for detecting chromosomal abnormalities and mosaicism to increase pregnancy success rates[1][3][4].

Therapeutic areas: Rare DiseasesWomen's Health
Modalities: Diagnostic testGenomic analysis (Comparative genomic hybridization, array CGH, SNP arrays)
Industry: Molecular Diagnostics

Partnerships

Collaborated with more than 20 institutes globally to advance PGD technology.

Beyond the preview

Go deeper on Reprogenetics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Reprogenetics.

Explore the full profile